Edwards Lifesciences Corporation · NYSE:EW
Edwards Lifesciences — 2021 Edwards Lifesciences Investor Conference
15 slides from Edwards Lifesciences's conference presentation, Dec 8, 2021
Slide 1: Surgical Structural Heart
Surgical Structural Heart Daveen Chopra Corporate Vice President Surgical Structural Heart
Slide 2: Surgical Structural Heart is transforming patients' lives
Surgical Structural Heart is transforming patients’ lives by solving critical unmet needs in cardiac surgery The surgical structural heart market will continue to grow mid-single digits to $2B by 2028 We closely partner with surgeons to understand and address unsolved challenges in surgery We are pi
Slide 3: The surgical structural heart market continues to grow
The surgical structural heart market continues to grow Cardiac surgery remained a high priority throughout the COVID pandemic Improved awareness and diagnosis of structural heart disease is contributing to the growth of the global structural heart market As more patients are diagnosed, referrals to
Slide 4: Edwards Surgical continues to bring leading innovation
Edwards Surgical continues to bring leading innovation Through Transformative Our Patient Focus Impacts Lives Globally Innovation Pioneering more resilient Redefining tissue Increasing global surgical therapies that durability standards with patient access and help patients live longer robust clinic
Slide 5: RESILIA tissue improves durability through its novel anti-calcification properties
RESILIA tissue improves durability through its novel anti-calcification properties Clinical Need Investing in long-term, real-world evidence on durability The primary mode of failure for tissue valves is calcification Feasibility Multi-Center Multiple Clinical Study Pivotal Trial Post-Market Studies
Slide 6: Increasing global adoption of RESILIA accelerates long-term growth
Increasing global adoption of RESILIA accelerates long-term growth RESILIA Tissue Valves Aortic Mitral Bovine Tissue Valves INSPIRIS KONECT MITRIS Aortic valve Aortic valved conduit Mitral valve Porcine Our RESILIA portfolio is empowering patients to engage in Tissue Valves surgical valve choice for
Slide 7: INSPIRIS is the leading surgical aortic valve in the world
INSPIRIS is the leading surgical aortic valve in the world Designed with expandable VFit technology, enabling potential future valve-in-valve procedures More than 5 years of promising clinical data on RESILIA Driving global access to accelerate conversion to premium tissue valves 12/8/2021 7
Slide 8: KONECT is a ready-to-implant tissue conduit for complex aortic patients
KONECT is a ready-to-implant tissue conduit for complex aortic patients Only device on market that simplifies difficult, combined aortic valve and root surgeries This segment, best addressed surgically, is forecasted for double-digit growth in the US Rapidly increasing adoption of this specialized,
Slide 9: MITRIS is designed to improve durability by withstanding higher pressures in the mitral valve
MITRIS is designed to improve durability by withstanding higher pressures in the mitral valve Enhanced ease-of-use for implantation and valve-in-valve compatibility Leading mitral valve in Japan six months post-launch; US launch planned for 2022 Long-term growth opportunity as 60% of global mitral v
Slide 10: Significant opportunity to grow and accelerate patient impact in emerging markets
Significant opportunity to grow and accelerate patient impact in emerging markets Adult cardiac surgery continues to grow quickly in emerging regions due to increased awareness, diagnosis, and wealth Surgery remains the predominant treatment option, and most patients receive mechanical valves that r
Slide 11: Two opportunities for innovation in a growing surgical mitral repair market
Two opportunities for innovation in a growing surgical mitral repair market Innovating Premium Surgical Repair Therapies Helping surgeons achieve excellent, consistent When performed well, surgical mitral procedural outcomes repair is the most durable treatment option and restores patients to their
Slide 12: 2022 Underlying Global Sales Growth Outlook
2022 Underlying Global Sales Growth Outlook Headwinds $950M Tailwinds Continued TAVR conversion Adoption of in developed markets $870M RESILIA products Accelerated COVID recovery mechanical-to-tissue valve conversion 2022E Underlying Global Surgical Estimated Sales Growth Mid single-digits 12/8/2021
Slide 13: In Summary
In Summary ▪ The Surgical Structural Heart market is anticipated to grow mid-single digits, including growth in surgical aortic valve replacement ▪ 2022 growth driven by the adoption of our RESILIA platform, becoming the new standard of care for surgical patients ▪ We will continue to extend patient
Slide 14: Important Safety Information: RESILIA Tissue Devices
Important Safety Information: RESILIA Tissue Devices Indications: INSPIRIS RESILIA Aortic Valve - For use in replacement of native or prosthetic aortic heart valves. KONECT RESILIA Aortic Valved Conduit - For use in replacement of native or prosthetic aortic heart valves and the associated repair or
Slide 15: | PE TN
| PE TN Re IND, a ve Edwards Helping Patients is Our Life’s Work, and, now) fife”
Edwards Lifesciences — 2021 Edwards Lifesciences Investor Conference on 6ix